We recently published a list of 10 Best Pharma stocks to buy for long -term growth. In this article, we will look at the place where Merck & Co.
With the presence of large American pharmaceutical companies that are always looking for medicines in China, the American pharmaceutical industry is going through an unprecedented unique direction before. About 30 % of the major drug acquisitions that included at least 50 million dollars in 2024 included Chinese companies, according to Dealforma statistics, CNBC reported. This was an increase of 20 % in the previous year and about 0 % only five years ago.
Experts cite several reasons for this trend. Some people believe that Chinese pharmaceutical companies draw a notice because of their skills in the field of advanced development, which enables them to produce strong vehicles in large quantities. In addition to the ability to start testing on human themes more quickly, these Chinese companies can impose a lower price of these drugs from the United States. Buyers have developed a work strategy that enables them to import medicines through licensing agreements, according to CNBC. The scarcity of investment capital in China is additional pressure on biotechnology companies to enter these agreements.
Experts believe this position here to survive, although there are many possible reasons for this trend. Although the American pharmaceutical industry is expected to be affected, it is certain how these effects appear. If major pharmaceutical companies find a good Chinese drug at a low price, some experts believe that it may destroy American startups; Others believe that competition will benefit the sector. Tim Obler, Managing Director of the Stifel Global Health Care Group, has stated the following regarding the circumstances:
“It is the moment of the water -like water gatherings,” we don’t really need to buy biotechnology for us. We’ll do that if this is logical, but we can buy completely good biotechnology assets through licensing deals with Chinese companies. “
Emily Field, Head of European Pharmaceutical Research in Barclays, spoke to CNBC on February 20 about obesity drugs, American tariff effects, and pharmaceutical dynamics. According to her, at least in the first half of this year, the industry may not perform badly. The effectiveness of obesity drugs is still a discussion, as the leading companies in this field showed inconsistent results in the past.
Speaking of the definitions, she stated that since some companies collect their products in the United States after their production abroad, their implementation raises many questions that have not been answered for the drug industry. Thus, these companies have relatively low manufacturing costs, an important factor that must be taken into account when assessing the effects of definitions. I thought these companies could easily absorb the upper expenses of definitions. This topic did not come much to profit calls in this quarter, and the market approaches the end of the reports season.
For this article, we have examined companies working in the pharmaceutical industry. From that list, we have set the arrows that have achieved positive growth in revenue over the past five years. After that, we chose companies that have achieved 5 years growth by 10 % and ranked first ten based on the morale of hedge funds as of the Q4 2024, according to the Monkey database from the inside.
Why are we interested in the arrows that accumulate hedge boxes? The reason is simple: Our research showed that we can outperform the market by imitating the best stock choices for the best hedge boxes. The quarterly newsletter strategy chooses 14 small stocks of large and large rule every quarter, and has returned by 373.4 % since May 2014, overcoming its standard by 218 percentage points (See more details here).
Is Merck & Co. , Inc. (MRK) is the best Pharma stock to buy for long -term growth?
A close image of a person’s hand carries a bottle of medications.
Number of hedge boxes: 91
Merck & Co. , Inc. (NYSE: MRK) is a vital pharmaceutical product company that provides healthy solutions to enhance the treatment and prevention of diseases in animals and individuals. Vaccines and pharmaceutical goods are available for human health, which usually include treatment and preventive materials, through the medicine department. The animal health department creates, finds it, produces, and sells a variety of veterinary vaccines and medicines.
Merck & Co. sales are affected , Inc. (NYSE: MRK) negatively with certain factors. For example, due to the decrease in appreciation spending, the distribution of the HPV to China until mid -2025. The company maintains excellent operations despite these short -term difficulties, which are strengthened by the high demand for its innovative and varied wallet. Keytruda cancer treatment in the company works well, and the introduction of Winrevair, which is a drug for high arterial blood pressure (PAH), also helps to increase the growth of revenues.
The Hider Lion, Goldman Sachs’s analyst, remained optimistic about the stocks and classified it as a purchase on April 8. The analyst feels that the animal health department at Merck & Co. As one of The best pharmaceutical stocksThe analyst believes this provides investors with a pricing opportunity.
Greenskeeper Asset Management, an investment management company, has released the q3 2024 investor speech. here It is what the fund said:
“Merck & Co., INC. (NYSE: MRK) was the second largest selected in this quarter, as it decreased by -8.3 %. The pioneering HPV vaccine in MRK, Gardasil 9, has faced challenges at the short level, and faces stock in the long term, where you expect to give up the cabinet. Keytruda continues Cancer Juggernaut $ 27 billion in a healthy clip, which leads to profit growth.
Generally, mrk Second rank In our list is one of the best drugs to buy for long -term growth. While we acknowledge the capabilities of pharmaceutical companies, our condemnation lies in the belief that artificial intelligence shares are more promises to make higher returns, and do so in a shorter time frame. Amnesty International has increased since the beginning of 2025, while famous artificial intelligence shares have lost about 25 %. If you are looking for Amnesty International’s more promising from MRK but is trading less than 5 times its profits, check our report on this The cheapest inventory of artificial intelligence.
Read the following: 20 best Amnesty International purchase shares now and 30 best shares for purchase now according to billionaires.
Detection: Nothing. This article was originally published in A monkey from the inside.
